Moderna is due to report its second-quarter financial results on Friday ahead of the market open, a day after announcing ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Analysts have given Moderna a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target ...

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before the bell. Here’s what to expect.

Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for ...

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine. After experiencing remarkable growth during the pandemic with its groundbreaking ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about MRNA stock here.

An explosive phase of growth may be ahead thanks to several potential product launches. A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA). Once ...

It also intends to present data from the P304 study at a future medical meeting. MRNA Stock Price Performance Post the above news, shares of Moderna rose nearly 2% yesterday.